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DID THE FDA PROPERLY ASSESS THE SAFETY OF 
OLESTRA AS A FOOD ADDITIVE? 
Leah Lebel 
INTRODUCTION 
Olestra, a fat-substitute comprised of sucrose that has been esterified with fatty acids 
(Blume 1995), has been the subject of much controversy ever since its creation. Olestra is not 
absorbed (Mattson and Nolen 1972) because it cannot be hydrolyzed by pancreatic lipases 
(Mattson and Volpenhein 1972) or taken up across the enterocyte microvillus membrane 
(Freston et al. 1997), and thus, cannot be utilized for energy. Olestra has physical and 
organoleptic properties similar to those of traditional triglycerides (Jandacek and Webb 
1978) and is emulsified together with triglyceride (Freston et al. 1997), yet it passes through 
the colon and is excreted unchanged (Fallat et al. 1976). It therefore adds no fat, sugar, or 
calories to the diet (Thomson et al. 1998) 
There is a noteworthy advantage of replacing fat with olestra: olestra is far less energy-
dense than its triglyceride counterpart and can, at least in theory, be a valuable asset to a 
weight-loss regimen. Olestra can serve to satisfy one’s cravings for fatty-foods without 
containing the dense energy that triglycerides provide (Eldridge et al. 2002).  By causing a 
reduction in energy intake for consumers, olestra, when incorporated with other calorie-
saving methods, has the potential to cause weight loss when replaced with more energy-dense 
products (Rolls and Bell 1999). 
After Procter & Gamble, the makers of olestra, obtained their first patent on olestra in 
1971 (Nestle 1998), olestra underwent a more than 20-year struggle until it was finally 
approved in January 1996 (Nightingale 1996). Much of the controversy surrounding this 
food additive stems from its versatility, as olestra can withstand high heating temperatures 
and can be used in virtually any food(Eldridge et al. 2002), and from its potential to be 
consumed in large quantities. Olestra presents a potential danger in that it is a macro-additive; 
a serving of olestra-containing food has several grams of the additive, rather than milligrams 
(as artificial sweeteners and many other additives have). This fact presented an 
unprecedented decision for the FDA—it was now choosing to approve something that would 
be consumed in potentially substantial quantities. Nevertheless, on January 25th 1996, the 
FDA released its ruling that olestra was to be approved for use in savory snacks. The FDA 
did, however, require that vitamin losses typically experienced from consuming olestra 
(particularly fat-soluble vitamins) be added to compensate for these losses. Thus, vitamins A, 
Figure 1: The chemical structure of olestra as compared with traditional triglyceride  
Source: http://extoxnet.orst.edu/faqs/additive/olstru.htm 
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D, E, and K are added to olestra during manufacturing. Initially upon approving olestra, the 
FDA, still unsure about long-term safety at 
approval time, required a warning notice 
for all products (Nestle 1998) stating that 
“This Product Contains Olestra. Olestra 
may cause abdominal cramping and loose 
stools. Olestra inhibits the absorption of 
some vitamins and other nutrients. 
Vitamins A, D, E, and K have been added” 
(Center for Science in the Public Interest).      
Much consumer controversy resulted from olestra’s approval (Miller 2001). From 
olestra’s entry into the market, there have been tens of thousands of adverse anecdotal reports 
from olestra consumers. People claimed they had suffered severe diarrhea, fecal incontinence, 
and/or abdominal cramps hours after eating olestra chips. Procter & Gamble, however, 
claimed that there is no proof that olestra is the cause of these effects (Center for Science in 
the Public Interest).      
The Center for Science in Public Interest (CSPI) in particular was infuriated with 
olestra’s passing into market and constantly collected data in an attempt to convince the FDA 
to withdraw their decision. Many other groups and independent challengers also believe that 
olestra should not have obtained FDA approval. They challenged the studies conducted by 
Procter & Gamble, pointing to the fact that some studies conducted by Unilever, Procter & 
Gamble’s competition, show that olestra, when consumed at high levels, causes 
gastrointestinal problems in up to 30% of subjects, point to the large marketing campaigns 
used to promote the product, and claim that significant losses of fat-soluble vitamins, and 
particularly carotenoids, can increase the risk of chronic diseases. Yet because critics could 
not prove that carotenoid losses were harmful and because the product had a label warning of 
GI distress potential, no action was taken to remove the product from the market (Nestle 
1998).  According to Porterfield, “the PDA [sic] granted approval [of Olestra] acknowledging 
that some patients may experience abdominal cramps and diarrhea if they eat too much” 
(Porterfield 1997). 
In 2003, the FDA chose to eliminate the requirement for a warning label, stating that it 
“was no longer warranted as post-market studies showed that olestra caused only infrequent, 
mild gastrointestinal effects” (FDA removes olestra warning 2003).  
Michael F. Jacobson, the executive director of CSPI, notes, "P&G's own studies prove 
olestra causes diarrhea, cramps and other symptoms. If that weren't enough, the FDA has 
more than 20,000 complaints about olestra in its files--more than it has for all other food 
additives in history combined” (FDA removes olestra warning 2003). In a post marketing 
surveillance study, .4% of consumers were hospitalized, and suspected olestra to be the cause 
for their hospitalization (Allgood et al. 2000). Other consumers pointed to other side effects 
such as headaches and blame olestra as the cause (Blume 1995). Nonetheless, there is no 
direct proof that this is the case. As Procter and Gamble noted in their defense, it is quite 
possible that there was another unrelated cause to all these ailments and that experiencing 
ailments at some time after consuming olestra was a coincidental occurrence. 
Despite this, many people began to question the FDA’s approval of olestra. Many ask: 
how has the FDA been able to responsibly pass into market a product that may not be safe for 
such large segments of the population who may not realize the effects of olestra on their 
overall health? Olestra causes side effects of great magnitude; diarrhea, after all, can cause 
Figure 2: Sample of the warning label originally 
required on all olestra-containing products 
Source: http://www.carboh.com/olestra.phtml 
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complications including weight loss, dehydration and electrolyte imbalances (Tortora and 
Derrikson 2006). Moreover, Procter and Gamble contributed funds to the FDA, just weeks 
before the FDA actually approved olestra (Nestle 1998). Thus, many wonder if olestra is safe 
and if the decision was based solely on fact. 
This study attempts to determine whether the FDA took the necessary scruples to 
avoid prematurely allowing olestra into market. An analysis of the standards utilized by the 
FDA, followed by a comparison of those standards with the research is warranted.   
WHAT ARE THE CRITERIA UPON WHICH THE FDA MAKES ITS “SAFE” OR 
“UNSAFE” RULINGS?  
ADDITIVE REGULATION GUIDELINES WHICH THE FDA ADHERES TO:  
In an article aimed at explaining the requirements and procedures involved in the 
FDA’s additive-approval process, Rulis and Levitt (2009) depict many of the factors that 
would explain what Procter and Gamble, the company that manufactures olestra, would have 
had to undergo to get olestra approved for consumer use.  The article notes the fact that the 
FDA requires that additives undergo a strict approval regimen and employs an “unsafe until 
proven safe” mentality: “New food additives are presumed to be unsafe for their intended use 
unless and until they are proven ‘safe’” (Section 3; 2008). The additive in question must meet 
with the FDA’s standards of “reasonableness to cause no harm.” Clearly, “reasonableness to 
cause no harm” is a subjective term and thus in the article’s appendix, the author elaborates on 
just what “reasonableness” is defined as. Section 409(c)(3) of the FD&C act explains that the 
food additive in question requires a “fair evaluation of the data” and that the concept of safety 
involves the question of whether a substance is “hazardous to the health of man or animal.” 
Primarily, calling a product “safe” requires proof of “a reasonable certainty that no harm will 
result from the proposed use of an additive” (House of Representatives, Report No. 2284, 85th 
Congress, 1958, as qtd. in appendix 10 of Rulis and Levitt 2009).  Thus, in assessing the safety 
of olestra, the FDA would have been expected to determine (1) whether olestra could 
potentially be hazardous to the health of man or animal and if the substance in question has a 
reasonable certainty to cause harm based upon the data available prior to olestra’s approval 
date on January 25th 1996.  
 The authors of the articles also reference the House of Representatives Report 
No 2284, 85th congress, 1958 statute 21CFR 170.3(i)) which elaborated upon the term “safe” 
to mean “a reasonable certainty in the minds of competent scientists that the substance is not 
harmful under the intended conditions of use” (italics added). It is important to note that, in this 
ruling, there must be a reasonable certainty only. In other words, the product in question is 
not guaranteed to be safe, but rather, it must present itself as reasonably harmless to health. 
Rulis and Levitt adeptly point out that this wording does “[result]in decisions inevitably being 
made without absolute certainty” (appendix 10).The burden to provide proof of safety lies 
with the petitioner (Rulis and Levitt 2009), and therefore Procter and Gamble would have 
had to demonstrate to the FDA that there is reasonable certainty that the item causes no harm 
in the minds of competent scientists. Hence, the questions that remain for this research paper 
to address is (2) were the competent scientists company based (and thus possibly biased) or 
were they independent researchers and (3) how credible are the studies upon which the 
scientists were basing their decision? A critical review of the literature available until olestra 
became approved is warranted in order to assess the meticulousness of the scruples taken 
before the FDA’s decision was finalized. At least in theory, the research should have been able 
to persuade the FDA of olestra’s reasonable safety. 
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Another inquiry to the above is what is olestra’s “intended condition of use”? Rulis and 
Levitt’s journal article then goes on to explain that “[there are] a range of technical functions 
in food…as outlined by Food Ingredients, as outlined in a brochure produced jointly by the 
FDA in collaboration with the international Food Information Council.”  The article then goes 
on to list some of these technical functions, and the one that best fits olestra would be the 
second one, or, “to improve or maintain nutritional value,” which includes the point of 
“lowering the calorie or fat content of foods.” Hence, reducing the energy consumed would be 
considered a sufficient benefit of the product’s use. The purpose of reducing the energy 
content of a specific food would, in turn, be to lower the weight-gain by the consumer who 
chose to consume the food with the additive rather than the one without. In an age where 
obesity is reaching epidemic proportions (World Health Organization 1998), this is an 
important task to be accomplished. Over a long period, even modest caloric-reduction benefits 
can translate into significant weight loss. In light of this, olestra’s use serves a very important 
function to lower the skyrocketing obesity rate. Thus, it is probably safe to infer that the 
“purpose” or benefit seen by the FDA for olestra’s use would be to produce a weight-loss 
effect in the obese, thus opening a fourth underlying question that would provide the 
justification, or lack thereof, of ruling for olestra’s approval:(4) whether olestra actually 
causes weight reduction in those who would benefit from weight loss. Section three of the 
article then goes on to state that “once approved, food additives must be safe for everyone—
children and the very young; teenagers and adults; the elderly; pregnant and lactating 
women.” This fact obviously raises a fifth question: how does olestra consumption affect those 
who may experience negative consequences resulting from a lower energy consumption (such 
as pregnant women who require a higher caloric intake to support a growing fetus or children 
reaching puberty who also require a higher energy intake to support growth spurts and 
maturation) and can these subgroups easily meet these increased energy needs while 
consuming lower-calorie versions of fat such as olestra. The FDA would have had to assess 
this (5) and would have had to provide special labeling so special-risk subpopulations can be 
properly informed, if necessary that they must avoid the product. At present, no food labels 
are featured on the package of olestra-containing products.  Also, along with the question of 
whether olestra promotes weight loss, is a further question: does it lower the health risks 
associated with Obesity (6), such as the low-density lipoprotein (LDL)or serum triglyceride 
levels. (7) Does the added vitamin K promote coagulation and hinder the effects of warfarin 
therapy? (8) How does olestra interact with lipophilic drugs?  
HOW MUCH DID THE FDA APPROVE AS SAFE? 
CALCULATED ESTIMATED DAILY INTAKE (EDI): 
In FDA’s assessment of an additive’s safety they consider the probable intake of the 
additive, the cumulative effect of all uses of the additive, and the relevant toxicological data 
needed to establish its safety (Rulis and Levitt2009). The FDA determined that the estimate 
for daily chronic intake was a mean of 3.1 grams per day, with the 90th percentile consumption 
at 6.9 grams per day. Even among the highest consumer levels (teens and men) the estimate 
for daily chronic intake was as low as 11.0 grams per day at the 90th percentile level. 
Primarily, 7 grams per day would be considered, according to the FDA, the average chronic 
consumption level. Because a 2-ounce bag of chips contains about 20g of olestra, the chronic 
consumption level would be in effect from one consuming merely about .75 ounces daily 
(Prince and Welschenbach 1998), or about 8 chips daily.  
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POTENTIAL PROBLEMS AND BENEFITS ASSOCIATED WITH OLESTRA 
CONSUMPTION 
WHAT PROCTER AND GAMBLE SUBMITTED TO THE FDA FOR OLESTRA’S 
APPROVAL:  
According to an article published in the Journal of the American Dietetic Association 
(Prince and Welschenbach 1998), Procter and Gamble provided data in five categories: the 
estimated daily intake (EDI), toxicological effects, olestra’s effect on drug absorption, 
nutritional effect, and gastrointestinal effect. This study will provide both the studies 
submitted to the FDA before olestra’s approval and the numerous studies from independent 
research pursuits that occurred subsequent to olestra’s approval to provide an independent 
and comprehensive evaluation and answer not only if the FDA’s decision was appropriate, but 
what effects of olestra that had not been found that may have been available had the FDA 
waited longer before approving olestra.   
TOXICOLOGICAL EFFECTS: 
From studies performed on several animal species including rats, pigs, rabbits, mice, 
hamsters, and dogs, the FDA decided that the data supported the petitioner’s conclusions for 
olestra’s non-toxic and non-carcinogenic properties and that olestra is neither metabolized nor 
absorbed by the body(Prince and Welschenbach 1998). Many people pinpoint the fact that no 
human studies were conducted before FDA approval. While the reasoning behind this 
remains unanswered, the FDA had obviously believed that testing olestra on animals was 
sufficient for determining the safety for the general population’s consumption.  
OLESTRA’S POTENTIALLY NEGATIVE EFFECTS ON CAROTENOID 
CONCENTRATION, 2,3,7,8 TETRACHLORODIBENZO-P-DIOXIN (TCDD) AND 
DRUG ABSORPTION 
Hof and Weststrate (1995)concluded that, “Even at low doses, SPE[sucrose polyester] 
strongly reduces plasma carotenoid concentrations.” 
“Sucrose Polyester and Plasma Carotenoid Concentrations in Healthy Subjects,” concluded 
that, “Even at low doses, SPE strongly reduces plasma carotenoid concentrations. Studies 
suggest that carotenoids have provitamin A activity as well as antioxidant properties (Faulks 
and Southon 1997) and cause a reduced incidence of hypertension and cataracts (Thomson et 
al.1998). On the surface, therefore, this finding would appear to merit “careful consideration 
in its relevance to assessing the long-term health effects of SPE-containing consumer foods” 
(Hof and Weststrate 1995). A subsequent study, however, posits that although olestra would 
have an effect on potentially beneficial phytosterols, this effect would be miniscule and 
nutritionally insignificant (Cooper et al. 1997). Moreover, there is no scientific proof that 
carotenoids contribute to health and wellbeing. Therefore, the FDA determined that the 
assertion of olestra’s negative impact on dietary carotenoid level did not warrant attention and 
did not deem it appropriate to force the company to add compensatory carotenoids to olestra-
containing snacks (Thomson et al. 1998).     
Another possible issue with olestra is that it increases fecal excretion of 2,3,7,8 
tetrachlorodibenzo-p-dioxin (TCDD) by eight to ten fold. In turn, this reduces the 
elimination half-life of TCDD by about 5 years. The article’s author states that these 
compounds may diffuse across the intestinal wall along the concentration gradient of the 
chemical between lumen fat and blood fat. This, according to the author, “would be expected 
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to increase the capacity of the lumen to take up lipophilic contaminants in the blood” (Geusau 
1999). The results of this could be problematic but more needs to be assessed before 
conclusions can be drawn from this study.   
Olestra is a lipophilic substance and therefore has the potential to affect the 
bioavailability of lipophilic drugs (Prince and Welschenbach 1998).  In a 1990 study 
performed on rats, the researchers found little possibility for severe drug malabsorption due to 
olestra’s presence.  At first, the researchers hypothesized that “any effect that a nonabsorbable 
lipid, such as olestra, might have on the absorption of an oral drug will result primarily from 
interference with incorporation of that drug into the intestinal mixed-micelles by solubilization 
of the drug in the nonabsorbable lipid. The more lipophilic the drug is, the higher the potential 
for it to be solubilized by the lipid. The lipophilicity of a drug can be described by its oil-water 
partition coefficient…” (Miller et al. 1990) In other words, a highly lipophilic drug has far 
more potential to be affected by the presence of olestra simultaneously in the GI tract than a 
drug with modest lipophilicity. While Miller et al. (1990) found that “there is little potential 
for olestra to reduce absorption of oral drugs in general,” it is up to competent doctors to 
recognize this and inform patients when olestra may affect the drugs the patient is taking. In 
theory, a patient’s treatment can be hindered in the rare instance where olestra does inhibit a 
lipophilic drug’s absorption and therefore a drug’s efficacy is reduced. However, this is 
unlikely, particularly when adhering to the acceptable daily intakes established by the FDA. 
Another study performed on humans was also reviewed by the FDA, yet in this study, the 
experimental group’s result data does not differ from the control group’s (Prince and 
Welschenbach 1998), and therefore the FDA concluded, based on this study and the one 
conducted by Miller et al. (1990), that “olestra does not interfere with the absorption or 
bioavailability of lipophilic drugs…when administered at the 18g/day level” (Note that this is 
above the FDA approximated toxicity level). Still, it is important to underscore the fact that 
there is no direct proof that olestra does not hinder drug absorption and more research is 
warranted to assess the correlation (although minute) found by Miller et al. 
GASTROINTESTINAL EFFECTS OF OLESTRA:  
The FDA required two 56-day studies to determine the gastrointestinal effects plus a 
4-week multicenter study on patients with inflammatory bowel disease, ulcerative colitis and 
Crohn’s disease. Tests for those in the 4-week study were used to determine if olestra’s 
presence in the GI tract aggravates already damaged epithelium. There was no statistically 
significant increase in bowel permeability, but the FDA decided that the study was too 
narrowly-ranged to rule out detrimental effects that olestra may have on gastrointestinal 
diseases (Food additive petition 7A3997 volumes 192-194 submitted Feb 1993 and volumes 
183-184 submitted January 5th 1993 as cited in Prince and Welschenbach 1998).     
Clinical trials following olestra’s approval pointed to side effects experienced by some 
and sparked adverse publicity about olestra. This prompted Procter and Gamble to establish a 
panel of experts to independently analyze the studies relating to olestra and digestive system 
function. Procter and Gamble agreed to submit the panel of experts’ findings regardless of 
their conclusions. The panel convened in September 1996 and “analyzed data from preclinical 
and clinical studies pertaining to the chemistry of olestra, its mechanism of action, and its 
potential for gastrointestinal effects” (Freston et al. 1997). An article published in Regulatory 
toxicology and pharmacology reviewed and analyzed olestra’s effects on gastrointestinal functions 
and the symptoms experienced as a result of olestra consumption as determined by this board 
(Freston et al. 1997).  
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From the results of clinical trials, the board found that in a study in which subjects of 
the experimental group were consuming 18g of olestra daily rather than triglyceride, no 
statistically significant difference between the two groups with respect to bloating, belching, 
heartburn, nausea, cramping, or diarrhea was found. However, in two studies that involved 
consumption of 20 grams of olestra or more per day, “there was an increase in the number of 
symptom episodes and the total number of days on which symptoms were reported” (Freston 
et al. 1997). Another striking revelation about these two studies is that symptoms were 
reported several days after olestra ingestion. This allows for possibility that other studies of 
very short durations may not have had enough time elapse after olestra consumption for 
symptoms to appear, and therefore might have under-reported symptoms.  
The group established by Procter and Gamble also reviewed studies of children. In the 
three studies that this board reviewed, no significantly worse incidence of symptoms has 
occurred in studies performed on children than on those performed in adults.  
Obviously, consideration must be taken in realizing that the group of reviewers was 
funded by Procter and Gamble. Although this did not necessarily influence the findings of the 
group, it may have done so.     
Post marketing surveillance for olestra via an established toll-free number reported 85 
reports during the first 9 weeks. There were 65 incidences in diarrhea, 64 of cramping, and 16 
of nausea among others. These are pertinent side effects that warrant attention (Freston et al. 
1997). It is not known how much olestra the reporters of side-effects consumed. Not 
necessarily were these symptoms caused from olestra, and it is likely that at least some of the 
reports may have been misattributed to olestra. Nonetheless, the overwhelming number of 
people who suspected side-effects from olestra should necessitate more research in this area.  
Other studies, including two sponsored by Procter and Gamble, including one which 
fed 20 to 32 grams of olestra, which, granted, is more than the FDA recommends, showed 
significant dose-related increases of diarrhea, loose stools, and an increase the severity and 
frequency of GI symptoms (Jacobson and Brown 1998). A rechallenge study confirmed this 
(at the 20g consumption per day level) and a similar study conducted over the course of 5 
days found a significant increase in adverse GI effects at the 34g/day level.  
In 1998, researchers conducted an experiment in a movie-setting (Cheskin et al. 1998) 
whereby subjects who were randomly selected to consume olestra chips were compared to 
those who were not. Of the more than 1,000 people studied, there was no statistically 
significant difference in gastrointestinal effects of the two groups. This serves to support the 
FDA decision. Note that in this study, the amount of olestra consumed by many subjects 
exceeded four servings. This supports the widened gap between the amount approved by the 
FDA (around 8 chips) and the amount consumers are actually ingesting.  An important 
observation of this study is that consumers were given a 13-ounce bag of chips, but no 
measures were taken to check how much, or if any, olestra-containing (or regular) chips were 
actually consumed. This slightly invalidates the conclusion because the experimental group 
may not have consumed the chips. 
In 2000, the Annals of Internal Medicine published a study that tested for steatorrhea, 
the presence of above-normal amounts of fat present in feces, in individuals who consumed 
olestra (Balasekaran et al. 2000). The purpose of the study was to determine the effect of 
olestra consumption on fecal fat excretion. “If olestra increases the amount of measurable fecal 
fat,” the researchers hypothesized,“ physicians may suspect the malabsorption syndrome in 
patients who consume olestra and may subject them to unnecessary diagnostic tests” 
(Balasekaran et al. 2000). The researchers found that “by all three analytical methods [which 
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they used], apparent concentration of fecal fat was higher when the ten participants were 
consuming olestra chips than when they were consuming conventional chips” (Balasekaran et 
al. 2000).  The mean number of bowel movements per day was significantly higher when 
subjects consumed olestra. “Olestra consumption increased stool frequency, wet stool weight, 
percentage of stool solids (measured by lyophilization), and fecal output of both water and 
solids. The output of fecal solids increased by an average of 36.2 g/d, which almost equals the 
quantity of Olestra ingested.” (Balasekaran et al. 2000) In addition, fecal fat output increased 
as consumption of olestra did, a fact that seems to indicate the possibility that olestra causes 
loose or greasy stool. The article also mentions that “when stool from participants who were 
ingesting olestra was stained…more than 100 orange-red fat droplets were found per high-
power field. Drop diameters ranged from 6 to 120 µm. The size and number of the fat droplets 
were not noticeably different after acidification and heating, which suggests that olestra was 
excreted intact rather than as a fatty acid” (Balasekaran et al. 2000). Nonetheless, steatorrhea, 
although uncomfortable, is not necessarily harmful and this would not have hindered the 
FDA’s approval of the product.  
Overall, there seems to be an increase in olestra-related side-effects in some studies 
where the amounts of olestra that the experimental group’s subjects consumed exceeded the 
amount recommended by the FDA.  
DOES OLESTRA HAVE OTHER BENEFITS SUCH AS LOWERING LOW DENSITY 
LIPOPROTEIN (LDL) CHOLESTEROL LEVELS OR SERUM TRIGLYCERIDE 
LEVELS?  
Studies have shown that olestra does lower LDL levels when olestra replaces 60g of 
saturated fat in the diet (far more than the FDA approved as safe) (Glueck et al. 1982). LDL 
levels were reduced without a significant reduction in High-Density Lipoprotein (HDL) 
levels. It is important to note that this change in cholesterol level may not necessarily be due 
to olestra’s presence in the diet (and the possibility that it inhibits cholesterol absorption), but 
rather may be a mere result of lower saturated fat consumption (Miller et al. 1990). 
Another study in which 50 grams of olestra was substituted for an equal weight of fat 
showed that olestra consumption has no effect on plasma triglyceride levels (Fallat et al. 
1976). Serum triglycerides are also decreased after a meal containing olestra as compared with 
a meal containing triglyceride of equal amounts  (as contrary to above where there was no 
significant relationship). Coronary blood flow was greater after olestra consumption above 
(Cook et al. 2000). 
In general, there are health benefits of consuming olestra; however, these benefits 
appear when consuming olestra in exorbitant amounts. The FDA has not proved such large 
quantities as safe. 
DOES THE ADDED VITAMIN K IN OLESTRA AFFECT PATIENTS RECEIVING 
WARFARIN THERAPY?  
Moderate intake of olestra does not seem to affect patients who are receiving long-term 
warfarin therapy despite the added Vitamin K in olestra (Beckey et al. 1999; Holbrook et al. 
2005). 
ARE THE STUDIES THAT WERE REVIEWED BEFORE FDA APPROVAL 
COMPANY-BASED OR OTHERWISE RESEARCHED?  
Petitioners must show the FDA proof of safety; the FDA does not have its own 
allocated funds for independent evaluation. Thus, the research is provided by the petitioner 
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seeking to get the additive approved (Nestle 1998). This addresses question three above: were 
the “competent scientists” company based?  
IS OLESTRA’S INTENDED FUNCTION OF USE, WEIGHT LOSS, LIKELY? 
There is mixed data regarding whether or not substitution of olestra for fat will result 
in weight loss or gain of weight. In theory, substitution of a higher caloric product with a 
lower caloric product would result in fewer calories consumed, and thus weight loss over the 
long term. Studies have demonstrated that when subjects consume lower-calorie, yet similar-
appearing (portion-wise) meals, they do consume fewer calories from their meals (Bell and 
Rolls 2001). If one can consume the same serving size of a lower-calorie product and thereby 
save oneself over fifty calories per serving, thousands of calories per month, and possibly tens 
of thousands per year duration can theoretically be saved(Rolls and Bell 1999). In practice, 
however, this is may not be the case because consumers may compensate for their caloric 
deficits or consume more because they feel that it is a “diet” product.  
The FDA approved olestra in 1996. Perhaps by examining the studies done prior to 
the approval date, a better analysis of the limited data available to the FDA can be obtained. 
 STUDIES PRIOR TO OR DURING OLESTRA’S APPROVAL 
In a study conducted in 1994, researchers found that when lean males were fed 55 
grams of sucrose polyester (far more than the FDA approved) during meals or throughout the 
day, they did not consume more during subsequent meals or throughout the following day. 
Hence, the males consuming sucrose polyester, as compared with those consuming 
triglyceride consumed a reduced total fat and energy intake over the 2-day study. There were 
no reported increases in hunger ratings (Burley et al.1994).In a subsequent study the same 
group fed their experimental groups of lean males the same 55 grams of sucrose polyester to 
replace triglyceride, but this time replacing it specifically at lunch or evening meals. The 
results were consistent with those from the previous study; energy intake and subjective 
hunger ratings (both following the meal and during the next day) of those consuming sucrose 
polyester were not significantly different from the control group consuming triglyceride. 
Again, this resulted in a decreased energy intake over the 2-day study (Cotton et al. 1996a). 
Other studies, such as the two studies done by Hulshof et al. (1995a and b), one by feeding 
normal weight adults buttered croissant preloads after a duration of food-deprivation which 
ranged from .25-4.75 hours and one by giving subjects high-carbohydrate preloads, seemed to 
agree that, when fat is replaced by a polyester substitute, a caloric deficit (and thus eventually 
potential weight loss) would result. 
A study performed in weanling pigs, an animal with a GI tract similar to small 
children, suggested that olestra is not absorbed in children (like adults) (Dahler et al. 1996). 
Young children, however, do seem to compensate for the caloric deficit created by 
substituting full-fat foods for olestra-containing counterparts. In a 1993 study, 29 small 
children (ages 2-5) were studied to determine the compensatory effects of consuming olestra. 
The children were fed diets of either 10% fat or 10% non-fat triglyceride substitute. Children 
who consumed fat-substitute wound up consuming more on a subsequent day and the total 
energy intake difference was only approximately 100 kJ(kilojoules) over 2 days. Children 
adjusted their energy intake to replace the energy deficit from consuming the fat substitute 
rather than actual fat. Therefore, the use of fat-substitute did not produce a noticeable caloric 
deficiency in these children(Birch et al.1993).Eldridge et al. (2002)propose a rationale for this 
compensation: “Young children may regulate energy intake more precisely because of their 
high energy demands relative to body size. Food consumption in children may also be 
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influenced more by physiological factors than in adults in whom external factors may play a 
greater role.” Nonetheless, the same principle is evident when olestra is fed to another group 
requiring high-energy needs per kg of body weight: lean young men. Apparently, it is not only 
children, but also other groups with higher caloric needs, that compensate calories lost by a 
higher consumption later on. Other authors reported that when olestra was substituted for 
fats in diets of lean men, the subjects completely counteracted the effect of the non-caloric 
replacer they were fed (namely, it created an energy deficit) and consumed more, balancing 
the energy intake to match the subjects who consumed the full-fat energy counterparts over 
course of the study (Rolls et al. 1992). This addresses question five (5) of this paper—the 
FDA would not have had to place targeted group warnings to those who would experience 
adverse effects from caloric reduction because the members of these subgroups compensate 
for the imposed caloric deficits.   
STUDIES FOLLOWING OLESTRA’S APPROVAL THAT MAY HAVE AIDED THE 
FDA HAD THEY BEEN AVAILABLE EARLIER 
In a long-term study (9 months) performed by Bray et al. (2002) on overweight and 
obese men, subjects randomly received either a diet of 33% fat (diet A), a diet of 25% fat (diet 
B), or a diet of 25% fat plus 8% of their diet from a fat substitute (diet C). Diet C contained 
the palatability of enough fat equivalent to Diet A. Essentially, although it appeared to the 
subjects given Diet C that they were consuming the amount of fat present in Diet A, they 
were actually consuming a fat percentage resembling that of diet B, yet due to the presence of 
fat-substitute, made the fat content appear (or taste) larger than it actually was. Diet A serves 
as the control in the study; diet B mimics a traditional low-fat diet whereby fat content is 
reduced by 8% of total daily caloric intake, and diet C resembles the traditional diet but is 
actually reduced fat.  While subjects of all groups were required to consume their diets, all 
groups were entitled to consume more of fixed-composition foods if desired. All groups lost 
weight over the first three months of the study, but over the next six months, members of the 
control (diet A) maintained the weight they reached after the three weeks, members of diet B 
(the low-fat diet without substituted olestra for the missing fat content) regained some weight 
and those consuming Diet C (the low-fat diet plus olestra to substitute for the fat) continued 
to lose weight (Bray et al. 2002). This study, although done after olestra was FDA approved, 
seems to indicate that over the long-term, when olestra replaces a portion of the diet’s fat 
content, weight loss results.  A similar study performed on women displayed that when 
subjects have access to products which are normally restricted on diets (such as olestra-
containing potato chips) they feel less deprived and are more likely to comply with their diets 
(Bolton et al. 1996).    
How would olestra’s possible compensatory mechanism differ when olestra is found in 
liquids? Rolls et al. (1992) conducted a study whereby creamed soup (high-fat and non-fat 
(made with olestra)) was fed to subjects.  This study was done on both normal-weight and 
obese-weight subjects and follow-up intake (the next meal) did not differ. Consequently, those 
consuming olestra-containing soup consumed a lower energy level over the course of the 
study, indicating that olestra consumption in liquid form does not promote compensatory 
overeating.  
In another study, in groups of both normal weight and obese people of both genders, 
researchers substituted a tenth of some of the subjects’ diets’ fat at breakfast and dinner with 
olestra while some consumed traditional triglyceride. These results concur that total energy 
and fat intake was lower for subjects consuming olestra rather than triglyceride because, 
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although subjects did compensate for a percentage of the caloric deficit they assumed when 
consuming olestra, they nevertheless did not compensate for the total caloric reduction (Hill et 
al.1998). 
Some presumed that the availability of a fat-free potato chip product would translate 
into a belief for consumers that they can eat as much as they desired without consequences. 
Because olestra provides no energy, foods made with olestra are considerably less energy 
dense than the full-fat options or other reduced-fat alternatives in which fat energy is 
substituted with carbohydrates.  “There are concerns that consumption of reduced-fat foods, 
such as olestra, can lead to unrestrained eating if consumers believe these foods are calorie 
free. There is some research that consumers do not substitute equal amounts of high-fat with 
reduced fat foods; but rather, they may eat larger portions of reduced fat products.” (Satia-
Abouta et al. 2003)      
Many worried that consumers would use the availability of fat-modified food products 
as a rationale to eat more of the reduced-fat food; they may falsely assume that it won’t 
significantly affect weight-gain (Rolls and Miller 1997).  In 1998, The American Journal of 
Clinical Nutrition published a study designed to test whether the knowledge that a product is 
fat free would result in more chips consumed by subjects. Ninety-five subjects were divided 
into groups of those informed about the fat-free product and those uninformed.  The results 
demonstrated that indeed, along with knowledge that a product is “dietetic,” comes a desire to 
consume more of that product. Unrestrained subjects consumed significantly larger amounts; 
however, because the product was lower in fat and calories, they consumed fewer calories as 
compared with the full-fat chip eaters (Miller 1998). This study seems to indicate that the 
FDA’s approval would be worthwhile. Yet it’s important to note the side effects encountered 
during the study among those consuming fat-free chips. The author states “There were no 
significant differences in the occurrence of illness or malaise related to the consumption of the 
two types of potato chips” (Miller 1998). This may have been the case when referring to 
headaches, cold, and flu symptoms, but there were five complaints of menstrual discomfort 
and eight reports of vertigo and dizziness from those consuming fat-free chips and no 
complaints for those consuming regular chips. Additional studies may be in order to determine 
if olestra is a potential cause for these symptoms.  None of the effects or symptoms hindered 
subjects from continuing to participate in the study. Thus, although they may have been 
present, they were probably not very severe. Also, because the study was only ten days in 
length, it is not known if there are any long-term side effects. The study found: “No significant 
changes in body weight occurred in any group as a result of consuming either type of potato 
chip over the 10-d periods.” This seems odd considering the fact that those consuming fat-free 
chips were ultimately consuming fewer calories from the chips. It is possible that the caloric 
savings were modest, and thus the product was not eaten over a long enough duration for the 
net calorie savings to appear as pounds lost (or not gained as compared to those eating regular 
chips)and that that changes in weight would have become apparent had the study continued 
over a longer period of time. It is also possible that the subjects were compensating the 
calories saved due to a stimulated appetite or subsequent hunger caused by the fat-free chips 
(in a similar mechanism to aspartame and other macronutrient substitutes). In either case, the 
study demonstrated that at least, over the short term, no significant weight loss results from 
the substitution of olestra in chips for fat and that indeed, consumers compensate the amount 
and eat more when aware that the product contains fewer calories (Miller et al. 1998).  
In a study designed to measure the relationship between olestra consumption and 
changes in dietary intake, serum lipids, and body weight, participants were required to fill out 
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a thorough food questionnaire; researchers characterized subjects according to both weight 
and olestra intake. Subjects were “normal weight,” “overweight,” or “obese” and either had no 
olestra intake (0g/d), very low intake (0-.4g/d), low intake (.4-2g/d), or moderate/high intake 
(2 or more grams daily). In one ounce of a snack food containing olestra, there are eight 
grams of olestra, and thus those were classified as “moderate/high intake.”  This group was 
eating only one quarter or more of a serving per day, which essentially translates into only five 
chips per day. Only two percent of the sample fell into the high intake category. The sample 
included fewer than 1200 participants; thus, no more than twenty-four participants were 
considered to consume high intakes of olestra. As compared with a baseline clinic visit (before 
olestra had entered the market), carbohydrate intake increased by 37g/d and total energy 
increased by 209 kcal/day among high olestra consumers. Among non-olestra consumers, 
however, a decrease of 87 kcal/day and a carbohydrate intake decrease of 14 g/d were evident.  
The researchers concluded that there was no statistically significant relationship between the 
amount of olestra consumption and serum lipids or body weight. The article attributes the 
lack of significant findings to “the study sample [which] limited the ability of this study to 
detect significant effects” (Satia-Abouta 2003). 
These findings, however, cannot be taken at face value; BMI, and, correspondingly, 
weight (since BMI is essentially a height-weight ratio),is not the most accurate measure of 
one’s body fat (Burkhauser and Cawley 2008). Indeed, there are a number of factors, 
unrelated to body fat, which may affect a person’s weight, and thereby affect his/her height-
weight ratio, and therefore his/her BMI. For example, salt may cause a person to retain more 
water (Kumar and Berl 1998), making his/her body a heavier weight. Because the researchers 
only measured body weight, and not body fat, it cannot be assumed that excess body fat 
accompanied the excess weight gained from participants who consumed the chips. Yet this 
water-weight is short-lived and will disappear thereafter. Particularly because olestra is used 
for heavily-salty snacks, consumption of olestra would translate into increased sodium 
consumption as well. Thus, water retention may have caused the weight gain experienced by 
people in the study, and not the fat-substitute, olestra.      
There is also concern that olestra may adversely affect those with binge-eating 
disorders: “Clinical experience has shown that persons with bulimia and other binge-eating 
disorders are increasingly using fat-free foods during binge episodes. Because persons with 
bulimia are frequently mortified by their abnormal eating behavior, the use of fat-free foods 
allows them to feel less guilt and provides some self justification [sic] for their behavior 
because they are bingeing on “healthful” foods” (Hampl and Sheeley 1998).  In fact, to some 
bulimic people, the after-effects of consuming olestra may be considered a form of purging, as 
many Americans perceive olestra to have a laxative effect. (Hampl and Sheeley 1998).  
Apparently, this idea is believed, despite the fact that research results from a study have stated 
otherwise (Peters et al. 1997). Regardless of whether or not this concern is an accurate one, 
this prediction only became apparent after the FDA approved olestra, and hence, even if true, 
would not have been available to deter the FDA from allowing it to pass. More research is 
required in order to make definite claims for the possible danger of the binge-eating 
disordered population with olestra on the market.    
Cotton et al. found that, in general, the lower the percentage of fat in the diet 
remaining after the replacement of triglyceride with olestra, the more likely caloric 
compensation will occur(Cotton et al. 1996b). Therefore, modest substitutions of fat in the 
diet would result in lower compensation and greater likelihood for weight loss.  
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In a post marketing surveillance study (Patterson et al. 2000), heavy consumers of 
olestra (consuming more than 2.0g/d) had experienced a minor weight loss effect (.55 
kg/year) as compared with an even smaller weight-loss effect for those who were non-olestra 
consumers (.01 kg/year). In this study, olestra and weight loss seem to be insignificantly 
correlated. In fact, this serves to underscore the fact that, even with a large replacement of fat 
for olestra, large weight loss reduction does not necessarily result. Obviously, because this is 
merely a surveillance study, little is known about the people’s eating habits excluding olestra. 
It is possible that consumers of olestra ate more calorie-dense foods, and thus olestra did not 
cause weight loss despite a significant caloric reduction. Also, it is possible that those who do 
not consume olestra do not eat regular chips either and are generally more health-conscience. 
In sum, data on weight loss of olestra presents conflicting results from other studies. 
There is no reliable conclusion that can be drawn from the plethora of diverging statements 
and conclusions. 
REITERATION OF ANSWERS TO THE EIGHT QUESTIONS ABOVE:   
To recapitulate the answers to the eight questions posited: (1) Olestra can be 
potentially hazardous to the health of man or animal if consumed in amounts higher than 
those established as the toxicity level by the FDA. (2) The scientists whom the FDA used to 
evaluate olestra were company based. (3) A case-by-case analysis of individual studies was 
conducted throughout the research paper.(4) No conclusive statements can be made about 
olestra’s cause of weight loss (or lack thereof). (5)Olestra’s possible weight loss effect does not 
endanger subgroups that would be threatened by caloric deficiency because compensation 
occurs in groups who need the calories to maintain and/or gain weight. (6) Olestra seems to 
cause other benefits of weight loss such as lowering LDL cholesterol level and lowering serum 
triglyceride level when consumed in amounts greater than those stated as safe by the FDA. 
(7) Olestra’s vitamin K addition, when olestra-containing products are consumed within FDA 
allowed amounts, does not interfere with warfarin therapy. (8) When consumed within FDA’s 
proposed limits, olestra does not significantly interfere with lipophilic drugs. 
CONCLUSION AND DISCUSSION 
 In light of the fact that FDA only approved olestra in the amount of approximately 18 
grams or fewer per day, and in acknowledging that no statistically significant harmful data 
resulted from studies testing such small amounts of olestra, it is clear that the FDA did do a 
thorough assessment of the product when calculating the allowed amounts for consumption 
during data review. However, there seems to be a considerable mismatch between the amount 
of olestra the FDA approved for safe consumer use and what’s actually being promoted as a 
safe limit and consumed. The stated serving size on a package of olestra-containing Lay’s 
Light chips contains the amount of olestra that exceeds the amount approved by the FDA as 
safe. Moreover, in many of the studies reviewed (particularly those which resulted in side 
effects), it is clear that some people consume far more than one serving of chips. In order to 
avoid future side-effects experienced from olestra, there should be an emphasis placed on 
clearly informing the public of just how much olestra-containing product is at the safety level.  
Thus, better communication is vital in order to avoid potentially hazardous results.  
Some may argue, due to much inconclusive or hazily concluded research (particularly 
papers stating that more research is necessary before making any claims), that olestra had 
been approved prematurely to obtaining assurance of the product’s safety. While it is true that 
numerous studies have been conducted since olestra’s approval which may have shed more 
light on this controversial product, the FDA may have had to weigh the possibilities of 
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damaging effects that might have emerged from a study conducted later against a glaring 
negative consequence of the delay—a possible increase in obesity that could have been 
lessened if olestra had been approved earlier.  This is especially salient, as research bringing 
clear results may have taken a very long time to conduct; in fact, conclusive data from long-
term studies and determination of effects are still underway. 
While it is true that the FDA perhaps did approve olestra hastily and should have 
waited a bit longer until more published studies indicated the harmfulness (or lack thereof) of 
the product, it is important to remember that it is not the FDA’s job to be assured of consumer 
safety; they merely have to possess a reasonable certainty that a product does not cause harm. 
From the data, indeed there was a reasonable certainty. At a later date, when conclusive data 
can be drawn from the multitudinous conflicting opinions and study outcomes, the FDA can 
reassess and once again determine whether olestra’s market circulation is appropriate for the 
general population and the safety of the American consumer. 
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